The biotech industry is poised for continued growth in 2025, with Oneness Biotech launching its diabetic foot ulcer treatment, Fespixon, in China, while Panion & BF Biotech's nephropathy drug, Nephoxil, is expected to receive marketing approval from China’s National Medical Products Administration (NMPA). Meanwhile, OBI Pharma’s triple-negative breast cancer drug, OBI-822—developed from glycoscience technology licensed from former Academia Sinica President Chi-Huey Wong—is set for an interim analysis of its Phase III clinical trial, and Rock BioMedical aims to out-license its broad-spectrum vaccine after completing its Phase I trial in the first half of the year.
Read more
